文献速递流行病学与生物统计基础与转化研究

2型糖尿病肾病预测模型的系统综述与外部验证

Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study.
PubMed 文献 · BMJ · 2021-09-28

该系统综述与外部验证研究旨在识别和评估2型糖尿病肾病预后模型的质量与准确性,并在外部队列中验证。结果显示模型区分度与校准度在不同预测时间点和模型间差异较大,但每个结局均有特定模型在2、5、10年随访中表现出良好的区分与校准,且使用临床可获取的预测因子,适用于临床环境。

要点

  • 系统综述纳入41项研究共64个肾病预测模型,其中21个在Hoorn DCS队列外部验证。
  • 外部验证中,白蛋白尿、糖尿病肾病和慢性肾脏病模型在不同预测时间点性能差异较大。
  • 每个结局均有至少两个模型C统计量>0.8,且使用临床可获取预测因子,适合临床使用。

核心结论

  • 研究识别了多个预测白蛋白尿、糖尿病肾病、慢性肾脏病和终末期肾病的模型。
  • 外部验证中,各模型在不同预测时间点的区分度和校准度差异较大。
  • 每个结局均有特定模型在三个预测时间点显示良好区分度和校准度,且使用临床可获取预测因子,适用于临床环境。

研究设计与样本

  • 系统综述与外部验证,检索PubMed和Embase。
  • 纳入描述适用于2型糖尿病患者的肾病风险预测模型开发的研究。
  • 在GoDARTS队列中进行二次外部验证。

主要发现

  • 41项研究共报道64个模型,其中46个在糖尿病人群中开发,18个在一般人群中开发(将糖尿病作为预测因子)。
  • 46个糖尿病人群开发模型的表观区分度范围为0.60(95%CI 0.56-0.64)至0.99(未提供CI)。
  • 18个一般人群开发模型的表观区分度范围为0.59(未提供CI)至0.96(95%CI 0.95-0.97)。
  • 41项研究中有31项报告了校准度,模型总体校准良好。
  • 64个模型中有21个在Hoorn DCS队列中对白蛋白尿、糖尿病肾病和慢性肾脏病进行外部验证,不同预测时间点和模型间性能差异较大。

临床怎么用

  • 对于白蛋白尿、糖尿病肾病和慢性肾脏病,每个结局均有特定模型在2、5、10年预测中显示良好区分度和校准度,且使用临床可获取预测因子,可应用于临床环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify and assess the quality and accuracy of prognostic models for nephropathy and to validate these models in external cohorts of people with type 2 diabetes. DESIGN: Systematic review and external validation. DATA SOURCES: PubMed and Embase. ELIGIBILITY CRITERIA: Studies describing the development of a model to predict the risk of nephropathy, applicable to people with type 2 diabetes. METHODS: Screening, data extraction, and risk of bias assessment were done in duplicate. Eligible models were externally validated in the Hoorn Diabetes Care System (DCS) cohort (n=11 450) for the same outcomes for which they were developed. Risks of nephropathy were calculated and compared with observed risk over 2, 5, and 10 years of follow-up. Model performance was assessed based on intercept adjusted calibration and discrimination (Harrell's C statistic). RESULTS: 41 studies included in the systematic review reported 64 models, 46 of which were developed in a population with diabetes and 18 in the general population including diabetes as a predictor. The predicted outcomes included albuminuria, diabetic kidney disease, chronic kidney disease (general population), and end stage renal disease. The reported apparent discrimination of the 46 models varied considerably across the different predicted outcomes, from 0.60 (95% confidence interval 0.56 to 0.64) to 0.99 (not available) for the models developed in a diabetes population and from 0.59 (not available) to 0.96 (0.95 to 0.97) for the models developed in the general population. Calibration was reported in 31 of the 41 studies, and the models were generally well calibrated. 21 of the 64 retrieved models were externally validated in the Hoorn DCS cohort for predicting risk of albuminuria, diabetic kidney disease, and chronic kidney disease, with considerable variation in performance across prediction horizons and models. For all three outcomes, however, at least two models had C statistics >0.8, indicating excellent discrimination. In a secondary external validation in GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland), models developed for diabetic kidney disease outperformed those for chronic kidney disease. Models were generally well calibrated across all three prediction horizons. CONCLUSIONS: This study identified multiple prediction models to predict albuminuria, diabetic kidney disease, chronic kidney disease, and end stage renal disease. In the external validation, discrimination and calibration for albuminuria, diabetic kidney disease, and chronic kidney disease varied considerably across prediction horizons and models. For each outcome, however, specific models showed good discrimination and calibration across the three prediction horizons, with clinically accessible predictors, making them applicable in a clinical setting. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020192831.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Slieker RC, van der Heijden AAWA, Siddiqui MK, et al. Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study. BMJ. 2021. PMID: 34583929. doi:10.1136/bmj.n2134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。